A FLEXIBLE SENSITIVITY ANALYSIS APPROACH FOR UNMEASURED CONFOUNDING WITH MULTIPLE TREATMENTS AND A BINARY OUTCOME WITH APPLICATION TO SEER-MEDICARE LUNG CANCER DATA

被引:0
|
作者
Hu, Liangyuan [1 ]
Zou, Jungang [2 ]
Gu, Chenyang [3 ]
Ji, Jiayi [4 ]
Lopez, Michael [5 ]
Kale, Minal [6 ]
机构
[1] Rutgers State Univ, Dept Biostat & Epidemiol, New Brunswick, NJ 08854 USA
[2] Columbia Univ, Dept Biostat, New York, NY 10027 USA
[3] Brown Univ, Dept Biostat, Providence, RI 02912 USA
[4] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA
[5] Skidmore Coll, Dept Math, Saratoga Springs, NY 12866 USA
[6] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
来源
ANNALS OF APPLIED STATISTICS | 2022年 / 16卷 / 02期
关键词
Causal inference; ignorability assumption; observational data; Bayesian inference; nested multiple imputation; IMPUTATION; MODEL;
D O I
10.1214/21-AOAS1530
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
In the absence of a randomized experiment, a key assumption for drawing causal inference about treatment effects is the ignorable treatment assignment. Violations of the ignorability assumption may lead to biased treatment effect estimates. Sensitivity analysis helps gauge how causal conclusions will be altered in response to the potential magnitude of departure from the ignorability assumption. However, sensitivity analysis approaches for unmeasured confounding in the context of multiple treatments and binary outcomes are scarce. We propose a flexible Monte Carlo sensitivity analysis approach for causal inference in such settings. We first derive the general form of the bias introduced by unmeasured confounding, with emphasis on theoretical properties uniquely relevant to multiple treatments. We then propose methods to encode the impact of unmeasured confounding on potential outcomes and adjust the estimates of causal effects in which the presumed unmeasured confounding is removed. Our proposed methods embed nested multiple imputation within the Bayesian framework, which allow for seamless integration of the uncertainty about the values of the sensitivity parameters and the sampling variability as well as use of the Bayesian Additive Regression Trees for modeling flexibility. Expansive simulations validate our methods and gain insight into sensitivity analysis with multiple treatments. We use the SEER-Medicare data to demonstrate sensitivity analysis using three treatments for early stage nonsmall cell lung cancer. The methods developed in this work are readily available in the R package SAMTx.
引用
收藏
页码:1014 / 1037
页数:24
相关论文
共 50 条
  • [41] Racial disparities in outcome among head and neck cancer patients in the United States: An analysis using SEER-Medicare linked database.
    Suzuki, Ikumi
    Cullen, Kevin J.
    Mehra, Ranee
    Bentzen, Soren
    Goloubeva, Olga G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data
    Jennifer M. Weiss
    Jessica Schumacher
    Glenn O. Allen
    Heather Neuman
    Erin O’Connor Lange
    Noelle K. LoConte
    Caprice C. Greenberg
    Maureen A. Smith
    Annals of Surgical Oncology, 2014, 21 : 1781 - 1791
  • [43] COMORBIDITY MEASURES TO PREDICT OVERALL SURVIVAL TIME AMONG ELDERLY GYNECOLOGIC CANCER SURVIVORS IN THE US: AN ANALYSIS OF SEER-MEDICARE DATA
    Park, C.
    Lawson, K. A.
    Barner, J. C.
    Powers, D. A.
    Rascati, K. L.
    Wilson, J. P.
    VALUE IN HEALTH, 2017, 20 (05) : A88 - A88
  • [44] Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data
    Weiss, Jennifer M.
    Schumacher, Jessica
    Allen, Glenn O.
    Neuman, Heather
    Lange, Erin O'Connor
    LoConte, Noelle K.
    Greenberg, Caprice C.
    Smith, Maureen A.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (06) : 1781 - 1791
  • [45] Incidence, patterns of treatment, and survival among men newly diagnosed with advanced prostate cancer: An analysis of SEER-Medicare data.
    Beebe-Dimmer, Jennifer Lynn
    Ruterbusch, Julie J.
    Cooney, Kathleen A.
    Schwartz, Kendra L.
    Bolton, Adam
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis
    Owonikoko, Taofeek K.
    Ragin, Camille
    Chen, Zhengjia
    Kim, Sungjin
    Behera, Madhusmita
    Brandes, Johann C.
    Saba, Nabil F.
    Pentz, Rebecca
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    ONCOLOGIST, 2013, 18 (05): : 600 - 610
  • [47] Comparison of Wedge Versus Lobar Resection for Stage 1 Non-Small Cell Lung Cancer: A SEER-Medicare Analysis Reply
    Cao, Jinlin
    Hu, Jian
    ANNALS OF THORACIC SURGERY, 2018, 106 (04): : 1261 - 1261
  • [48] TRENDS IN PREVALENCE, TREATMENT PATTERNS, MYELOSUPPRESSION, AND BURDEN ON THE HEALTHCARE SYSTEM AMONG PATIENTS WITH SMALL CELL LUNG CANCER: A SEER-MEDICARE ANALYSIS
    Epstein, R. S.
    Nelms, J.
    Moran, D.
    Girman, C.
    Krenitsky, J.
    Chioda, M.
    VALUE IN HEALTH, 2021, 24 : S66 - S66
  • [49] Second Malignancies (SM) among Multiple Myeloma (MM) Patients Exposed to Bortezomib (Btz) and Other Treatments: An Analysis of the US SEER-Medicare Linked Database
    Gifkins, Dina
    McAuliffe, Megan
    Matcho, Amy
    Porter, Jane
    Chavers, Scott
    Ryan, Patrick
    Moride, Yola
    Ponsillo, Maria
    King, Jay
    Desai, Avinash
    Cakana, Andrew
    Esseltine, Dixie-Lee
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 464 - 465
  • [50] Photodynamic therapy for stage I and II non-small cell lung cancer A SEER-Medicare analysis 2000-2016
    Chhatre, Sumedha
    Murgu, Septimiu
    Vachani, Anil
    Jayadevappa, Ravishankar
    MEDICINE, 2022, 101 (11)